390585
Suberohydroxamic acid
95%
Synonym(s):
N,N′-Dihydroxyoctanediamide, SBHA, Suberoyl bis-hydroxamic acid
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Linear Formula:
[-(CH2)3CONHOH]2
CAS Number:
Molecular Weight:
204.22
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.22
Quality Level
Assay
95%
mp
153-155 °C (lit.)
SMILES string
ONC(=O)CCCCCCC(=O)NO
InChI
1S/C8H16N2O4/c11-7(9-13)5-3-1-2-4-6-8(12)10-14/h13-14H,1-6H2,(H,9,11)(H,10,12)
InChI key
IDQPVOFTURLJPT-UHFFFAOYSA-N
Related Categories
Biochem/physiol Actions
Suberoyl bis-hydroxamic acid (SBHA) is a Histone deacetylase (HDAC) inhibitor. SBHA inhibits the activity of HDAC1 and HDAC3 with IC50 values of 250 and 300 nM, respectively. SBHA inhibits proliferation, and induces apoptosis in several cancer cell lines. SBHA has been shown to activate Notch signaling in medullary thyroid carcinoma (MTC) cells.
related product
Product No.
Description
Pricing
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Li Ning et al.
The oncologist, 13(2), 98-104 (2008-02-29)
Medullary thyroid carcinoma (MTC) is a neuroendocrine (NE) malignancy that frequently metastasizes and has limited treatments. We recently reported that ectopic expression of Notch-1 in human MTC cells suppresses growth. The objective of this study was to evaluate the ability
Jiansen Li et al.
Oncology reports, 37(1), 458-464 (2016-12-23)
Anaplastic thyroid cancer (ATC), usually derived from well-differentiated thyroid cancers is one of the most lethal human endocrine malignancies. In the present study, we report that in human ATC tumor tissue samples exist undetectable Notch1 and the active Notch1 intracellular
Denisa Hrckova Drozdkova et al.
Anticancer research, 40(9), 4979-4987 (2020-09-04)
Multiple myeloma is a highly heterogeneous disease of clonal plasma cells. Histone deacetylase (HDAC) inhibitors are promising anticancer drugs but their precise mechanisms of actions are not well understood. Cell-cycle regulation and pro-apoptotic effects of two histone deacetylase inhibitors, suberohydroxamic
Mohamed Rahmani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(18), 4849-4860 (2014-07-30)
The aim of this study is to explore the efficacy and define mechanisms of action of coadministration of the PI3K/mTOR inhibitor BEZ235 and pan-HDAC inhibitor panobinostat in diffuse large B-cell lymphoma (DLBCL) cells. Various DLBCL cells were exposed to panobinostat
A Vashishta et al.
Neuromolecular medicine, 16(4), 727-741 (2014-07-27)
The nonselective inhibitors of class I/II histone deacetylases (HDACs) including trichostatin A and the clinically used suberoylanilide hydroxamic acid (SAHA, vorinostat) are neuroprotective in several models of neuronal injury. Here, we report that in cultured cortical neurons from newborn rats
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service